Abstract Details

Title Convergent Validity and Classification Agreement Between Traditional Cognitive Screening Instruments and a Novel, Electronic-based, Voice-recognition Cognitive Screening Tool

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-004

Objective his study aimed to investigate convergent validity and classification agreement between traditional cognitive screeners and a novel, electronic-based, voice-recognition cognitive screening tool (Intraneuron Memory Exam Screening, IME-S).

Background Mild cognitive impairment (MCI) often goes undetected. Traditional paper/pencil cognitive screeners (e.g., MMSE, MOCA, Mini MOCA) are widely utilized, but lack sensitivity to subtle cognitive change, lack specificity for the cause of decline, and are time consuming for medical staff to administer.

Design/Methods 73 patients (age range 37-87; 50.7% female) from a community-based neurology practice completed a traditional cognitive screener and IME-S. For IME-S, a verbal memory test and verbal fluency tests were administered on iPad using voice-recognition technology. We examined convergent validity between cognitive screener and IME-S scores using correlation analysis. To assess classification agreement, we conducted McNemar tests to compare the number of individuals classified as cognitively “normal” vs. “impaired” using the traditional screener (with standard cut-offs) versus IME-S (using 1SD or 1.5SD cut-offs).

Results We found statistically significant, though modest, correlations between the traditional screeners and IME-S scores (all p < .05): letter fluency (r = 0.38), animal fluency (r = 0.33), verbal learning (r = 0.29), verbal recall (r = 0.36). However, results showed significant classification disagreement between the two assessment modalities. Using a 1SD cut-off for IME-S scores, IME-S classified 89.0% of patients as impaired, while the traditional screener classified 67.1% as impaired (p < 0.001). Using a 1.5SD cut-off for IME-S scores, IME-S classified 80.8% of patients as impaired vs 67.1% with the traditional screener (p < 0.05).

Conclusions This study demonstrated convergent validity between traditional cognitive screeners and IME-S. Results suggest IME-S may be superior in detecting early cognitive decline compared to traditional screeners (e.g., MOCA). This study suggests IME-S may have the potential to maximize utilization and improve early detection of cognitive decline.

Authors/Disclosures
Gregory Sahagian, MD, FAAN PRESENTER	Dr. Sahagian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sahagian has received intellectual property interests from a discovery or technology relating to health care.
Maddeline Sadoff	No disclosure on file
Angelina Tretola	No disclosure on file
Allison Kaup	No disclosure on file
Jacob N. Hall, MD (The Neuron Clinic)	Dr. Hall has nothing to disclose.
Lori Alalsantro	No disclosure on file
Jay Rosen (The Neurology Center of Southern California)	No disclosure on file
Vidar Vignisson	Vidar Vignisson has stock in Intraneuron, LLC. Vidar Vignisson has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��